Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy

Acta Oncologica

Volumn 55, Issue 12, 2016, Pages 1392-1399

  Hall, Matthew D ^a,b   Schultheiss, Timothy E ^a   Smith, David D ^a,c   Fakih, Marwan G ^a   Wong, Jeffrey Y C ^a   Chen, Yi Jen ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; RECTUM CARCINOMA; RECTUM RESECTION; TOTAL MESORECTAL EXCISION; TREATMENT RESPONSE; ABDOMINAL SURGERY; CANCER GRADING; CANCER STAGING; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; SURVIVAL RATE;

EID: 84992084626     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/0284186X.2016.1235797     Document Type: Article

References (28)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–40.
2. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years:increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693–701.
3. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers:results of FFCD 9203. J Clin Oncol 2006;24:4620–5.
4. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114–23.
5. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer:results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638–44.
6. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer:pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:2773–80.
7. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer:surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014;32:1927–34.
8. Schmoll HJ, Haustermans K, Rice TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer:disease-free survival at interim analysis. J Clin Oncol 2014;32:5s (suppl; abstr 3051).
9. Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study):final results of the multicentre, open-label, randomized, phase 3 trial. Lancet Oncol 2015;16:979–89.
10. van der Heijden GJ, Donders AR, Stijnen T, et al. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research:a clinical example. J Clin Epidemiol 2006;59:1102–9.
11. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011;29:3163–72.
12. Mohiuddin M, Paulus R, Mitchell E, et al. Neoadjuvant chemoradiation for distal rectal cancer:5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys 2013;86:523–8.
13. Wiltshire KL, Ward IG, Swallow C, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer:effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys 2006;64:709–16.
14. Garcia-Aguilar J, Shi Q, Thomas CR, Jr., et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer:preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012;19:384–91.
15. Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation:impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88:822–8.
16. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011;29:4633–40.
17. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer:does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008;71:1181–8.
18. Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279–86.
19. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer:the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396–402.
20. Pettersson D, Lörinc E, Holm T, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg 2015;102:972–8.
21. Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer:a multicentre, phase 2 trial. Lancet Oncol 2015;16:957–66.
22. Demetter P, Vandendael T, Sempoux C, et al. Need for objective and reproducible criteria in histopathological assessment of total mesorectal excision specimens:lessons from a national improvement project. Colorectal Dis 2013;15:1351–8.
23. Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012;30:1770–6.
24. Hall MD, Schultheiss TE, Smith DD, et al. Impact of total lymph node count on staging and survival after neoadjuvant chemoradiation therapy for rectal cancer. Ann Surg Oncol 2015;22:580–7.
25. Burbach JP, den Harder AM, Intven M, et al. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer:a systematic review and meta-analysis. Radiother Oncol 2014;113:1–9.
26. Appelt AL, Pløen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer:a prospective observational study. Lancet Oncol 2015;16:919–27.
27. Perez RO, Habr-Gama A, São Julião GP, et al. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer:do all patients benefit from waiting longer than 6 weeks? Int J Radiat Oncol Biol Phys 2012;84:1159–65.
28. Smith FM, Chang KH, Sheahan K, et al. The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg 2012;99:993–1001.